Shares of KalVista Pharmaceuticals KALV have soared 36% in the past week, all thanks to the FDA’s approval of its lead pipeline drug for the hereditary angioedema (HAE) indication. Earlier this week, ...

Short interest in KalVista Pharmaceuticals Inc (NASDAQ:KALV) decreased during the last reporting period, falling from 10.06M to 10.04M. This put 22.45% of the company's publicly available shares short ...

Pharmaceuticals announced that the Ministry of Health, Labor and Welfare in Japan has granted marketing and manufacturing approval ...

KalVista Pharmaceuticals, Inc. (KALV) key stats comparison: compare with other stocks by metrics: valuation, growth, profitability, momentum, EPS revisions, dividends ...

Shares of KalVista Pharmaceuticals, Inc. (KALV) have gained 30.5% over the past four weeks to close the last trading session at $8.22, but there could still be a solid upside left in the stock if ...

KalVista Pharmaceuticals develops oral small-molecule therapies for hereditary angioedema targeting plasma kallikrein and Factor XIIa. Sebetralstat completed Phase 3 trials and submitted an NDA in ...

KalVista Pharma (KALV) is scheduled to report earnings on December 13, 2024. The last reported earnings were for reported on September 5, 2024 for Q1.

Nasdaq Analyst Research provides analyst research for ratings consensus and a summary of stock price targets. Analysts evaluate the stock’s expected performance in a given time period based on their ...